Several brokerages have updated their recommendations and price targets on shares of Cullinan Therapeutics (NASDAQ: CGEM) in the last few weeks: 6/14/2026 – Cullinan Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”. 6/11/2026 – Cullinan Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $37.00 price target on the [...]